Radiochemical Synthesis and Evaluation of 3-[<sup>11</sup>C]Methyl-4-aminopyridine in Rodents and Nonhuman Primates for Imaging Potassium Channels in the CNS.

Authors:
Sun Y; Guehl NJ; Zhou YP; Takahashi K; Belov V and 5 more

Journal:
ACS Chem Neurosci

Publication Year: 2022

DOI:
10.1021/acschemneuro.2c00364

PMCID:
PMC9732819

PMID:
36417797

Journal Information

Full Title: ACS Chem Neurosci

Abbreviation: ACS Chem Neurosci

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neurology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"The authors declare the following competing financial interest(s): PB has a financial interest in Fuzionaire Diagnostics and the University of Chicago. PB is the inventor of a PET imaging agent owned by the University of Chicago and licensed to Fuzionaire Diagnostics. Dr. Brugarolass interests were reviewed and are managed by MGH and Mass General Brigham in accordance with their conflict-of-interest policies. The other authors declare no conflict of interests. Notes: P.B. has a financial interest in Fuzionaire Diagnostics and the University of Chicago. P.B. is the inventor of a PET imaging agent owned by the University of Chicago and licensed to Fuzionaire Diagnostics. P.B.’s interests were reviewed and are managed by MGH and Mass General Brigham in accordance with their conflict-of-interest policies."

Evidence found in paper:

"This study was supported by NIH R01NS114066 (P.B.), P41EB022544 (G.E.F.), and S10OD026987 (M.D.N. and G.E.F.)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025